Triple-negative breast cancer (TNBC) is a challenging subtype of breast cancer due to the lack of estrogen, progesterone, and HER2 receptors, which makes traditional hormone therapies ineffective. However, the exploration of phytochemicals as potential therapeutic agents has shown promise in the treatment of TNBC. Rigorous scientific investigation has revealed the anticancer efficacy of natural compounds found in plants such as Annona muricata, Erythrina variegata, Artocarpus hirsutus and more. These compounds have been found to disrupt critical cellular pathways in TNBC cells, including those regulating apoptosis and cell cycle progression. Additionally, they interfere with cancer cell signaling, promoting cell death and inhibiting tumor growth. The enhanced understanding of phytochemical interactions with cancerous cells underscores the potential for integrating these natural compounds into the broader strategy of TNBC treatment, leveraging their specificity and reduced toxicity for more effective and patient-friendly therapies. Furthermore, natural compound-based standalone or combination therapy could be utilized for the better management of TNBC, as these compounds are known for their minimal side effects and cost-effectiveness. Clinical trials have shown varying degrees of effectiveness, and while in vivo and in vitro data are promising, further basic and clinical investigations are required. The use of natural products in combination with other drugs may hold great potential for the treatment of TNBC. 

The research and development of nature-derived molecules underscore the vital role of natural products in the future of oncological treatment, especially in targeting challenging subtypes such as TNBC., Therefore, the exploration of natural compounds as potential therapeutic agents represents a promising advance in the treatment of TNBC, offering hope for the development of more effective and patient-friendly therapies.